Order Article Reprints

Hanssen A, Riebensahm C, Mohme M, Joosse SA, Velthaus J-L, Berger LA, Bernreuther C, Glatzel M, Loges S, Lamszus K, et al. Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease. Cancers. 2018; 10(12):527. https://doi.org/10.3390/cancers10120527

Hanssen, Annkathrin, Carlotta Riebensahm, Malte Mohme, Simon A. Joosse, Janna-Lisa Velthaus, Lars Arne Berger, Christian Bernreuther, Markus Glatzel, Sonja Loges, Katrin Lamszus, and et al. 2018. "Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease" Cancers 10, no. 12: 527. https://doi.org/10.3390/cancers10120527

Hanssen, A., Riebensahm, C., Mohme, M., Joosse, S. A., Velthaus, J.-L., Berger, L. A., Bernreuther, C., Glatzel, M., Loges, S., Lamszus, K., Westphal, M., Riethdorf, S., Pantel, K., & Wikman, H. (2018). Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease. Cancers, 10(12), 527. https://doi.org/10.3390/cancers10120527